Newton Biocapital
Overview
Newton Biocapital is a venture capital firm that invests in early-stage biotech and life science companies in Europe and Japan, with a focus on finding solutions for chronic diseases.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| AbolerIS Pharma | Sep 2023 | Series A | Co-investor |
| Bioxodes | Dec 2025 | Series B | Lead |
| Augustine Therapeutics | Mar 2025 | Series A | Co-investor |
| Santero Therapeutics | Jun 2023 | Series A | Lead |
| DeuterOncology | Jan 2023 | Series A | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Newton Biocapital based?
Newton Biocapital is headquartered in Brussels, Belgium.
When was Newton Biocapital founded?
Newton Biocapital was founded in 2017.
How many portfolio companies does Newton Biocapital have?
Newton Biocapital has 10 portfolio companies in Caplight's dataset.
What are some companies in Newton Biocapital's portfolio?
Portfolio companies visible on Caplight include AbolerIS Pharma, Bioxodes, Augustine Therapeutics, Santero Therapeutics, DeuterOncology.
What was Newton Biocapital's most recent investment shown here?
Newton Biocapital's most recent investment in this portfolio sample was in Bioxodes in 2025.
What sectors does Newton Biocapital focus on?
Newton Biocapital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Newton Biocapital focus on?
Newton Biocapital typically invests at the Early stage.
What is Newton Biocapital's AUM?
Newton Biocapital's assets under management are estimated between $167.0M and $264.0M.